Press release
Thyroid Cancer Clinical Trial Pipeline Analysis: 45+ Key Companies Shaping the Future of Thyroid Cancer Therapeutics | DelveInsight
Key takeaways from the Thyroid Cancer Clinical Trial Landscape Report
• DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 45+ companies working to develop 50+ pipeline therapies for Thyroid Cancer treatment.
• Key Thyroid Cancer companies such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Genentech, Sichuan Kelun-Biotech Biopharmaceutical, AffyImmune Therapeutics, Bayer, Gilead Sciences, Model Medicines, Biovista, Xynomic Pharmaceuticals, TYK Medicines, Solve Therapeutics, Pfizer, Fore Biotherapeutics, Beijing Scitech-Mq Pharmaceuticals Limited, and Sunshine Lake Pharma Co., Ltd.
• Promising Thyroid Cancer pipeline therapies in various stages of development include AL2846, Vemurafenib, A400, AIC100, Regorafenib, Sacituzumab govitecan, MDL-4101, BVA 701, XP-102, TY-1091, SLV-154, PF-07799933, FORE8394, ST-1898, and HEC169096.
Request a sample and discover the recent advances in Thyroid Cancer treatment drugs https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Thyroid Cancer?
Thyroid cancer is a malignant condition that primarily arises from the follicular cells of the thyroid gland, which are responsible for producing thyroid hormones. The major types of Thyroid Cancer include papillary, follicular, medullary, and anaplastic thyroid cancers, with papillary thyroid cancer being the most common and generally the least aggressive.
Symptoms may include a neck lump, hoarseness, difficulty swallowing, and swollen lymph nodes, although many early cases are asymptomatic. Risk factors include exposure to ionizing radiation, inherited genetic syndromes, and certain environmental and lifestyle factors.
Diagnosis has advanced through innovations in imaging, cytology, molecular testing, and artificial intelligence. Ultrasound remains a key diagnostic tool, while fine-needle aspiration cytology and molecular testing for alterations such as BRAF, RET, and RAS can support diagnosis and treatment selection.
Treatment is personalized according to cancer type, stage, and molecular profile. Surgery remains the primary treatment, while radioactive iodine therapy is commonly used for differentiated thyroid cancers following surgery. Thyroid hormone suppression therapy can help reduce recurrence risk. For advanced or iodine-resistant disease, targeted therapies such as tyrosine kinase inhibitors and mutation-specific inhibitors are being used.
Emerging Thyroid Cancer Drug Profiles
AL2846: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AL-2846 is an investigational small-molecule kinase inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. It targets receptor protein-tyrosine kinases, aiming to block cancer cell growth. The current trials are focused on its use in iodine-refractory differentiated thyroid cancer, both alone and in combination with other therapies, as well as neurofibromatosis type 1 and pancreatic cancer. Currently, the drug is being evaluated in Phase III clinical development for the treatment of Thyroid Cancer.
Vemurafenib: Genentech
Vemurafenib (Zelboraf) is an oral, small-molecule BRAF kinase inhibitor. The BRAF protein is a key component of the RAS-RAF pathway involved in normal cell growth and survival. Mutations that keep BRAF in an active state may result in excessive pathway signaling, leading to uncontrolled cell growth and survival. Vemurafenib is designed to block the BRAF mutation and may help kill cancer cells carrying the mutation or stop tumor growth. Currently, the drug is in Phase II clinical development for the treatment of Thyroid Cancer.
AIC100: AffyImmune Therapeutics
AIC100 is an affinity-tuned, third-generation CAR-T cell therapy engineered to target ICAM-1 on advanced thyroid cancers, including anaplastic and poorly differentiated thyroid cancers. ICAM-1, found on the surface of cancer cells, acts as a binding site for LFA-1 on AIC100 CAR-T cells, facilitating recognition and destruction of malignant cells.
AffyImmune Therapeutics has selected anaplastic and advanced differentiated thyroid cancers as the initial indications for AIC100. The therapy has received Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy designations from the FDA. Currently, AIC100 is in Phase I clinical development for the treatment of Thyroid Cancer.
Learn more about the novel and emerging Thyroid Cancer pipeline therapies https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Scope of the Thyroid Cancer Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Thyroid Cancer Companies: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Genentech, Sichuan Kelun-Biotech Biopharmaceutical, AffyImmune Therapeutics, Bayer, Gilead Sciences, Model Medicines, Biovista, Xynomic Pharmaceuticals, TYK Medicines, Solve Therapeutics, Pfizer, Fore Biotherapeutics, Beijing Scitech-Mq Pharmaceuticals Limited, Sunshine Lake Pharma Co., Ltd.
• Key Thyroid Cancer Pipeline Therapies: AL2846, Vemurafenib, A400, AIC100, Regorafenib, Sacituzumab govitecan, MDL-4101, BVA 701, XP-102, TY-1091, SLV-154, PF-07799933, FORE8394, ST-1898, HEC169096.
Dive deep into rich insights for new drugs for Thyroid Cancer treatment, visit https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Thyroid Cancer Pipeline Report Introduction
2. Thyroid Cancer Pipeline Report Executive Summary
3. Thyroid Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Thyroid Cancer Pipeline Therapeutics
6. Thyroid Cancer Pipeline: Late Stage Products (Phase III)
7. Thyroid Cancer Pipeline: Mid Stage Products (Phase II)
8. Thyroid Cancer Pipeline: Early Stage Products (Phase I)
9. Thyroid Cancer Pipeline: Preclinical and Discovery Stage Products
10. Thyroid Cancer Pipeline Therapeutics Assessment
11. Inactive Products in the Thyroid Cancer Pipeline
12. Key Companies
13. Key Products in the Thyroid Cancer Pipeline
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix
For further information on the Thyroid Cancer pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Thyroid Cancer Clinical Trial Pipeline Analysis: 45+ Key Companies Shaping the Future of Thyroid Cancer Therapeutics | DelveInsight here
News-ID: 4609076 • Views: …
More Releases from DelveIinsight Business Research LLP
Myositis Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future …
DelveInsight's Myositis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Myositis therapies in various stages of clinical development. The report provides insights into 40+ companies and 45+ pipeline drugs in the Myositis pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the Myositis Clinical Trial Landscape Report
• DelveInsight's Myositis pipeline report depicts a robust space with 40+ companies working…
Intracerebral Hemorrhage Clinical Trial Pipeline Analysis: 4+ Key Companies Shap …
DelveInsight's Intracerebral Hemorrhage Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Intracerebral Hemorrhage therapies in various stages of clinical development. The report provides insights into 4+ companies and 5+ pipeline drugs in the Intracerebral Hemorrhage pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the Intracerebral Hemorrhage Clinical Trial Landscape Report
• DelveInsight's Intracerebral Hemorrhage pipeline report depicts a developing…
Metastatic Prostate Cancer Clinical Trial Pipeline Analysis: 80+ Key Companies S …
DelveInsight's Metastatic Prostate Cancer Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Metastatic Prostate Cancer therapies in various stages of clinical development. The report provides insights into 80+ companies and 85+ pipeline drugs in the Metastatic Prostate Cancer pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the Metastatic Prostate Cancer Clinical Trial Landscape Report
• DelveInsight's Metastatic Prostate Cancer…
Hypoglycemia Clinical Trial Pipeline Analysis: 15+ Key Companies Shaping the Fut …
DelveInsight's Hypoglycemia Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Hypoglycemia therapies in various stages of clinical development. The report provides insights into 15+ companies and 20+ pipeline drugs in the Hypoglycemia pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.
Key takeaways from the Hypoglycemia Clinical Trial Landscape Report
• DelveInsight's Hypoglycemia pipeline report depicts a robust space with 15+ active…
More Releases for Thyroid
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Thyroid Function Test Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for thyroid function tests has witnessed substantial growth in the past few years. The market is projected to expand from $1.7 billion in 2024 to $1.81 billion in 2025, with an…
Rising Incidences of Thyroid Disorders Fuel Growth In The Thyroid Function Test …
The Thyroid Function Test Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Thyroid Function Test Market Size During the Forecast Period?
The thyroid function test market has grown significantly in recent years. It is expected to grow from $1.7 billion in 2024…
Thyroid Function Test Market Report 2024 - Thyroid Function Test Market Growth A …
"The Business Research Company recently released a comprehensive report on the Global Thyroid Function Test Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
Thyroid Ablation Devices Market
Alarming rise in prevalence of thyroid cancer, advancements in thyroid ablation system, rise in government & private funds for development of healthcare sectors, and increase in number of thyroid nodule cases are expected to notably contribute toward the growth of the global thyroid ablation devices market during the forecast period.
Rise in prevalence of thyroid cancer and thyroid nodules, demand for minimally invasive procedures, and technological advancements in ablation devices drive…
Thyroid Gland Disorders Treatment Market Increasing incidence of Autoimmune Dise …
The global market for thyroid gland disorders features a consolidated vendor landscape with a handful of companies accounting for a major chunk of the global market, observes Transparency Market Research in a recent report. In 2016, the thyroid gland disorders treatment market was dominated by Merck KGaA and AbbVie, Inc., which collectively accounted for more than half of the market. It has been observed that despite the large pool of…
Increasing Incidence of Thyroid Gland Disorders Expected to Propel the Thyroid G …
Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view…
